Presentation and Status in Health Basket
Presentation | Basket | Yarpa | Pharmasoft |
---|---|---|---|
Tablets 30 x 50 mg |
|
18667 | 9385 |
Tablets 30 x 100 mg |
|
18666 | 9386 |
Related information
Dosage
See prescribing information for full details.
Indications
NIDDM in patients inadequately controlled by diet alone, or on diet and oral hypoglycemic agents.
Contra-Indications
Hypersensitivity, pregnancy, lactation, chronic digestive system disorders, liver function disorders, renal insufficiency.
See literature for full details.
Special Precautions
When a high dosage is taken or when the medicdbine is taken concomitantly with other anti-diabetic medicdbations, hypoglycemia may occur, in which case glucose/dextrose should be administered rather than sucrose. May cause elevation in liver enzymes. Therefore, liver enzymes should be monitored during the first 6-12 months of treatment. Safety and efficacy in children under 18 years have not been established.
Side Effects
Increased flatulence, diarrhea, other abdominal aches. See literature for full details.
Drug interactions
Sulfonylureas, metformin, insulin, cholestyramine, digoxin, intestinal absorbents, and digestive enzyme preparations, activated charcoal preparations, neomycin.